Ribociclib-Letrozole Regimen Tested in Ovarian, Endometrial Cancer


Researchers examined the results of ribociclib and letrozole as a treatment for patients with estrogen receptor-positive ovarian cancer and endometrial cancer.

A phase II study found that the combination of ribociclib and letrozole showed promising activity in patients with estrogen receptor-positive ovarian cancer and endometrial cancer. The most benefit was observed in low-grade serous ovarian cancers.

“Up to 60% of ovarian tumors can be estrogen receptor (ER)-positive,” said Gerardo Colon-Otero, MD, of the Mayo Clinic in Jacksonville, Florida.

Previous trials of aromatase inhibitors in ovarian and endometrial cancer have been disappointing, but recent work showing good results when combined with cyclin kinase inhibitors, such as ribociclib, led to the new trial. Colon-Otero presented results of the study at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held May 31-June 4 in Chicago (Abstract 5510).

The phase II trial included 20 women with ER-positive ovarian cancer and 20 with ER-positive endometrial cancer. All patients received letrozole 2.5 mg daily and ribociclib 400 mg daily; they were treated until progression or unacceptable toxicity.

The median age in the ovarian cancer cohort was 61 years; in the endometrial cancer cohort, it was 64.5 years. Most patients in both cohorts had a performance status of 0, and most of the cohorts were white. Ovarian cancer patients had a median of three previous chemotherapy regimens; for those with endometrial cancer, the median was two previous regimens.

The study’s primary endpoint was met, based on the percentage of patients still alive and progression-free after 12 weeks (PFS12). The PFS12 in the ovarian cancer cohort was 50%, and 25% (five patients) were progression-free at 23 weeks. In the endometrial cancer patients, the PFS12 rate was 55%, and 45% were progression-free at 23 weeks.

Patients with low-grade serous ovarian cancer appeared to derive the most benefit, as all three patients were progression-free for at least 23 weeks; in fact, those three patients remained on therapy for more than 28, 24, and 19 months, respectively. Only 2 of the other 17 patients (12%) with ovarian cancer were progression-free at 23 weeks.

In the endometrial cancer patients, the most benefit was seen in those with grade 1–2 disease; 64% of those patients were progression-free for at least 23 weeks, compared with 22% of those with grade 3 disease.

The median PFS was 2.8 months in the ovarian cancer cohort, and 5.4 months in the endometrial cancer patients. The median overall survival in the two cohorts was 18.9 months and 15.7 months, respectively.

The most common treatment-related serious adverse events (AEs) included leukopenia (17.5%), neutropenia (15%), lymphopenia (7.5%), liver enzyme elevations (7.5%), and fatigue (5%). These were grade 3 AEs, with the exception of one case of grade 4 lymphopenia. There were no grade 5 AEs.

“Additional studies of this combination are indicated in ER-positive low-grade serous ovarian cancer, and grade one and two endometrial cancers,” Colon-Otero concluded.

Helen Mackay, MD, of the Princess Margaret Cancer Center in Toronto, discussed the study for ASCO. She agreed that these are “interesting data” and that larger, randomized trials are warranted. She noted, though, that some outstanding questions about the approach remain.

“Are the aromatase inhibitors the same in endocrine and gynecologic cancers as in breast?” she asked. “What’s going on in these pathways?... I’d encourage people to address the fundamental questions before moving into toxic combinations.”

Related Videos
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Related Content